• Explore /
  • Poster
  • / Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).

Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).

Abstract Poster

Authors

null

Seth Andrew Wander

Massachusetts General Hospital Cancer Center, Boston, MA

Seth Andrew Wander , Dejan Juric , Jeffrey G. Supko , Douglas Scott Micalizzi , Laura Spring , Neelima Vidula , Maureen Beeler , Karleen R. Habin , Elene Viscosi , Donna Michelle Fitzgerald , Lauren Scarpetti , Elizabeth Tripp , Rachel Hepp , Beverly Moy , Steven J. Isakoff , Leif W. Ellisen , Aditya Bardia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT03959891

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1066)

DOI

10.1200/JCO.2020.38.15_suppl.1066

Abstract #

1066

Poster Bd #

151

Abstract Disclosures

Similar Posters

First Author: Melinda L. Telli

First Author: Oana Cristina Danciu

First Author: Ayca Gucalp

First Author: Aditya Bardia